Drug class in one race
BRAF (V600 mutant) drugs for Non-Small Cell Lung Cancer
2 tracked BRAF (V600 mutant) drugs in the Non-Small Cell Lung Cancer race. The class explanation lives on the BRAF (V600 mutant) page; the full indication pipeline across every mechanism is on the Non-Small Cell Lung Cancer page.
1 Phase 2/31 preclinical / unstaged
Head-to-head evidence: ABM-1310 vs Vemurafenib